Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed in the UK for type 2 diabetes treatment, administered once weekly by subcutaneous injection
Improper technique denatures protein structure before injection ever occurs
Glycemic category was determined by investigators on the basis of available information (for example, medical records, concomitant medication, and blood glucose variables) and in accordance with American Diabetes Association criteria, 30 which for prediabetes includes fasting plasma glucose levels of 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) or HbA 1c levels of 5.76.4% (3947 mmol/L), and for type 2 diabetes includes fasting plasma glucose levels of 126 mg/dL (7.0 mmol/L) or HbA 1c levels 6.5% (48 mmol/L)
Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review
Not all alcoholic beverages fit into the above categories
While promising in animal studies, the blog emphasizes the need for further research and regulatory approval before human applications, offering insights into future peptide-based therapies